Abstract 4097
Background
Neuregulin 1 (NRG1) is a growth factor that binds HER3/4 and activates ErbB signalling pathways. NRG1 fusions function as oncogenic drivers and represent a potential therapeutic target across tumour types. Afatinib, an ErbB-family blocker, may be a treatment option for some patients (pts) with NRG1 fusion-positive (NRG1+) tumours, as supported by preclinical evidence and published case reports (Table).Table: 1969P
Patient | Tumour type | NRG1 fusion partner | Best response | Duration of response (months) | Reference |
---|---|---|---|---|---|
i | Non-mucinous lung ADC | SLC3A2 | PR | 12 | Gay, et al. J Thoracic Oncol 2017 |
ii | Non-mucinous lung ADC | SDC4 | PR | 12 | Jones, et al. Ann Oncol 2017 |
iii | IMA | CD74 | PR | 10 | Gay, et al. J Thoracic Oncol 2017 |
iv | IMA | CD74 | PR | 6.5 | Cheema, et al. J Thoracic Oncol 2017 |
v | IMA | CD74 | SD | 3 | Drilon, et al. Cancer Discov 2018 |
vi | IMA | SDC4 | PD | - | Drilon, et al. Cancer Discov 2018 |
vii | IMA | CD74 | PD | - | Drilon, et al. Cancer Discov 2018 |
viii | Cholangiocarcinoma | ATP1B1 | PR | 8 | Jones, et al. Ann Oncol 2017 |
ix | Pancreatic ADC | ATP1B1 | PR | 3 | Heining, et al. Cancer Discov 2018 |
x | Ovarian cancer | CLU | SD | - | Murumagi. AACR 2019, abs 2945 |
ADC, adenocarcinoma; IMA, invasive mucinous lung adenocarcinoma; PD, progressive disease; PR, partial response; SD, stable disease
Methods
We report clinico-pathological and molecular characteristics of seven previously unreported cases of afatinib-treated NRG1+ tumours.
Results
Pt 1, 70 yo female, never-smoker with pan-wildtype, non-mucinous lung adenocarcinoma (ADC) received 15th-line afatinib for 24 mos (PR). An NRG1 fusion was subsequently identified. The pt was re-challenged with afatinib (PR, 3 mos) before switching to atezolizumab (PD). Pt 2, 66 yo female, never-smoker with metastatic (m) non-mucinous lung ADC. CD74-NRG1 fusion was identified, and 5th-line afatinib initiated. PR is ongoing after 14 mos. Pt 3, 68 yo male, >20 pack-yr smoking history with non-mucinous lung ADC. SDC4-NRG1 fusion was identified and 2nd-line afatinib initiated. Best response: SD, 4 mos. Pt 4, 43 yo female, non-smoker with advanced invasive mucinous lung ADC. CD74-NRG1 fusion was identified and 3rd-line afatinib initiated; PR is ongoing. Pt 5, 69 yo male, with KRAS-mutated m-colorectal cancer. Following a right hemicolectomy and liver/lung metastasectomies, a novel POMK-NRG1 fusion was detected and afatinib initiated (SD, 4 mos; treatment ongoing). Pts 6 and 7, male (54 & 59 yo) with KRAS WT, m-pancreatic cancers. Following PD on chemotherapy, APP-NRG1 and ATP1B1-NRG1 fusions, respectively, were detected and afatinib initiated. Pt 6 had a PR for 5 mos; treatment ongoing. Pt 7 had a PR for 5.5 mos.
Conclusions
These findings add to a growing body of evidence suggesting that afatinib is a potential treatment option for pts with NRG1+ tumours. Prospective study is ongoing in the Drug Rediscovery Protocol trial (DRUP; NCT02925234).
Clinical trial identification
N/A
Editorial acknowledgement
Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Christina Jennings, of GeoMed, an Ashfield company, part of UDG Healthcare plc.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
S.V. Liu: Advisory / Consultancy: Apollomics; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Celgene; Advisory / Consultancy: G1 Therapeutics; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: Heron; Advisory / Consultancy: Ignyta; Advisory / Consultancy: Janssen; Advisory / Consultancy: Lilly; Advisory / Consultancy: Regeneron; Advisory / Consultancy: Takeda/Ariad; Advisory / Consultancy: Tempus; Advisory / Consultancy: Merck; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Taiho. M. Duruisseaux: Honoraria (self): Roche; Honoraria (self): Takeda; Honoraria (self): Pfizer; Honoraria (self): Novartis; Honoraria (self): AstraZeneca; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Merck Sharp and Dohme; Honoraria (self): AbbVie; Honoraria (self): Boerhinger Ingelheim. K. Tolba: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: Boerhinger Ingelheim; Honoraria (self): Merck; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Foundation One. Y. Goto: Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Eli Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Chugai; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Taiho Pharmaceuticals; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boerhinger Ingelheim; Speaker Bureau / Expert testimony, Research grant / Funding (self): Ono Pharmaceuticals; Speaker Bureau / Expert testimony, Research grant / Funding (self): Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Pfizer; Speaker Bureau / Expert testimony: Merck Sharp and Dohme; Speaker Bureau / Expert testimony: Shionogi Pharmaceuticals; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Novartis; Advisory / Consultancy: GSK; Research grant / Funding (self): AbbVie; Research grant / Funding (self): Dai-ichi Sankyo; Advisory / Consultancy: Kyorin. B.A. Weinberg: Travel / Accommodation / Expenses: Boehringer Ingelheim. D.J. Renouf: Honoraria (self): Celgene; Honoraria (self): Servier; Honoraria (self): Taiho; Honoraria (self): Ipsen; Honoraria (self): Bayer. R.C. Doebele: Advisory / Consultancy, Shareholder / Stockholder / Stock options, Licensing / Royalties: Rain Therapeutics; Honoraria (self): Guardant; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Trovagene; Advisory / Consultancy, Licensing / Royalties: Ariad; Advisory / Consultancy: Takeda; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy, Research grant / Funding (self), Licensing / Royalties: Ignyta; Advisory / Consultancy, Research grant / Funding (self), Licensing / Royalties: Loxo; Research grant / Funding (self): Mirati; Licensing / Royalties: Abbott Molecular; Licensing / Royalties: GVKbio; Licensing / Royalties: Chugai; Licensing / Royalties: Genentech; Licensing / Royalties: Foundation Medicine; Licensing / Royalties: Black Diamond. R.F. Schlenk: Research grant / Funding (self): Boehringer Ingelheim. P.K. Cheema: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Takeda; Honoraria (self), Advisory / Consultancy: Genomic Health; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Merck. J. Cadranel: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Lilly; Advisory / Consultancy: Merck Sharp and Dohme; Advisory / Consultancy, Research grant / Funding (self): Novartis; Advisory / Consultancy, Research grant / Funding (self): Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Takeda. M.R. Jones: Full / Part-time employment: Qiagen Inc. A.E. Drilon: Honoraria (self): Medscape; Honoraria (self): OncLive; Honoraria (self): PeerVoice; Honoraria (self): Physicians Education Resources; Honoraria (self): Tyra Biosciences; Honoraria (self): Targeted Oncology; Honoraria (self): MORE Health; Honoraria (self): Research to Practice; Honoraria (self): Foundation Medicine; Honoraria (self): Peerview; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Genentech/Roche; Honoraria (self), Advisory / Consultancy: Bayer; Advisory / Consultancy: Ignyta; Honoraria (self): Loxo; Advisory / Consultancy: TP Therapeutics; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Blueprint Medicines; Advisory / Consultancy: Takeda; Advisory / Consultancy: Helsinn Therapeutics; Advisory / Consultancy: BeiGene; Advisory / Consultancy: Hengrui Therapeutics; Advisory / Consultancy: Exelixis; Travel / Accommodation / Expenses, Other: Wolters Kluwer. L.A. Muscarella: Honoraria (self): AstraZeneca; Honoraria (self): Roche; Honoraria (self): Boehringer Ingelheim. A. Cseh: Full / Part-time employment: Boehringer Ingelheim; Shareholder / Stockholder / Stock options, Husband: Mylan. F. Solca: Full / Part-time employment: Boehringer Ingelheim RCV GmbH & Co KG. J.J. Laskin: Honoraria (self), Research grant / Funding (self): Roche Canada; Honoraria (self): Boehringer Ingelheim Canada; Honoraria (self): AstraZeneca Canada; Research grant / Funding (self): Pfizer Canada. All other authors have declared no conflicts of interest.
Resources from the same session
4822 - Efficiacy of different nutritional intervention on nutritional status and quality of life for local advanced nasopharyngeal carcinoma patients: a prospective clinical trial
Presenter: Yuan-yuan Chen
Session: Poster Display session 3
Resources:
Abstract
2628 - Apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma
Presenter: Changjuan Tao
Session: Poster Display session 3
Resources:
Abstract
4887 - Impact of tumor site and adjuvant radiotherapy on survival of adenoid cystic carcinoma: a SEER database analysis
Presenter: Jason Tasoulas
Session: Poster Display session 3
Resources:
Abstract
2634 - Efficacy and safety of anlotinib for patients with recurrent and/or metastatic salivary gland carcinomas
Presenter: Wen Jiang
Session: Poster Display session 3
Resources:
Abstract
3568 - ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): preliminary safety and efficacy data.
Presenter: Renata Ferrarotto
Session: Poster Display session 3
Resources:
Abstract
683 - Pathologic Staging Changes in Oral Cavity Squamous Cell Carcinoma—Stage Migration and Implications for Adjuvant Treatment
Presenter: Zain Husain
Session: Poster Display session 3
Resources:
Abstract
563 - Expression of immune response biomarkers in head and neck squamous cell carcinoma (HNSCC) in irradiated area
Presenter: Carole Pflumio
Session: Poster Display session 3
Resources:
Abstract
4030 - HLA-Ligandome analysis reveals target antigens of oropharyngeal squamous cell carcinoma
Presenter: Simon Laban
Session: Poster Display session 3
Resources:
Abstract
2979 - Topographical distribution of sentinel lymph nodes in early tongue squamous cell carcinomas
Presenter: Hiroyuki Goda
Session: Poster Display session 3
Resources:
Abstract
3517 - Role of follow-up (FU) FDG-PET/CT (FU-FDG-PET/CT) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) treated with chemotherapy and radiotherapy (RT), either concurrent (CRT) or sequential (ST).
Presenter: Bert Van Den Heuvel
Session: Poster Display session 3
Resources:
Abstract